Qun Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qun Chen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Alex X. Arreola
University of Oklahoma Health Sciences Center, United States
13 shared publications - Chao Xu
Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, USA
13 shared publications - Courtney W. Houchen
Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA
13 shared publications - Hao Yuan
University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
13 shared publications - Jingxuan Yang
Hematology-Oncology, Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
13 shared publications - Kuirong Jiang
Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
13 shared publications
Latest Publications
- Open Access
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Ferroptosis complements liver metastasis and TMB to predict immunotherapy outcomes. A, OS analysis of patients based on the status of liver metastasis and ferroptosis in tumor tissue in the IMvigor210 cohort. B, OS analysis of patients based on the status of liver metastasis and ferroptosis in tumor tissue in the Liu cohort. C, OS analysis of patients based on TMB and ferroptosis in tumor tissue in the IMvigor210 cohort. D, OS analysis of patients based on TMB and ferroptosis in tumor tissue in the Liu cohort. The log-rank test was applied for the survival analysis.
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Ferroptosis complements liver metastasis and TMB to predict immunotherapy outcomes. A, OS analysis of patients based on the status of liver metastasis and ferroptosis in tumor tissue in the IMvigor210 cohort. B, OS analysis of patients based on the status of liver metastasis and ferroptosis in tumor tissue in the Liu cohort. C, OS analysis of patients based on TMB and ferroptosis in tumor tissue in the IMvigor210 cohort. D, OS analysis of patients based on TMB and ferroptosis in tumor tissue in the Liu cohort. The log-rank test was applied for the survival analysis.
- Open Access
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S6 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S6. Correlation between TMB and ferroptosis in patients received immunotherapy.
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S6 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S6. Correlation between TMB and ferroptosis in patients received immunotherapy.
- Open Access
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S2. Progression-Free Survival of patients in Van-Allen cohort and Lauss cohort based on ferroptosis level.
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S2. Progression-Free Survival of patients in Van-Allen cohort and Lauss cohort based on ferroptosis level.
- Open Access
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Ferroptosis is associated with increased immunogenicity and favorable TIME subtypes. A–D, Compare the expression of ICD biomarker genes in ferroptosis-low and ferroptosis-high tumors in the IMvigor210 cohort. E, Examine the proportions of TIME subtypes in ferroptosis-low and ferroptosis-high tumors in the IMvigor210 cohort. F, OS analysis of patients based on TIME subtypes in the IMvigor210 cohort. G, OS analysis of patients based on cancer-immune phenotypes and ferroptosis levels in tumor tissue in the IMvigor210 cohort. *, P < 0.05; ***, P < 0.001. ANXA1, annexin A1; ATP8A2, ATPase phospholipid transporting 8A2; CALR, calreticulin; TPM, transcripts per million.
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Ferroptosis is associated with increased immunogenicity and favorable TIME subtypes. A–D, Compare the expression of ICD biomarker genes in ferroptosis-low and ferroptosis-high tumors in the IMvigor210 cohort. E, Examine the proportions of TIME subtypes in ferroptosis-low and ferroptosis-high tumors in the IMvigor210 cohort. F, OS analysis of patients based on TIME subtypes in the IMvigor210 cohort. G, OS analysis of patients based on cancer-immune phenotypes and ferroptosis levels in tumor tissue in the IMvigor210 cohort. *, P < 0.05; ***, P < 0.001. ANXA1, annexin A1; ATP8A2, ATPase phospholipid transporting 8A2; CALR, calreticulin; TPM, transcripts per million.
- Open Access
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S1. Correlation between ferroptosis level and overall survival of patients in Van-Allen cohort and Hugo cohort.
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S1. Correlation between ferroptosis level and overall survival of patients in Van-Allen cohort and Hugo cohort.
- Open Access
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Immunotherapy has revolutionized the treatment paradigms of several cancer types, yet only a subset of patients derives durable clinical benefit. Ferroptosis is a programmed cell death facilitated by iron-driven overload of lipid peroxidation. We aimed to evaluate ferroptosis activity based on tumor transcriptomic profiles to determine its predictive value for immunotherapy outcomes. We analyzed RNA sequencing data from eight independent cohorts of patients with urothelial, gastric, skin, and lung cancers treated with immune checkpoint inhibitors or adoptive T-cell therapy. A ferroptosis activity model was constructed using downstream gene expression signatures. Associations with overall survival and progression-free survival were assessed. Potential mechanisms were explored by examining immunosenescence, the IFN-γ immune response pathway, and immunogenic cell death. Ferroptosis-high tumors were associated with significantly improved overall survival and progression-free survival across multiple cancer types. Integrating ferroptosis scores with tumor mutation burden, liver metastasis status, and immune microenvironment phenotypes (inflamed, excluded, desert) enhanced patient stratification and predictive accuracy. Mechanistically, ferroptosis enhanced the immune response by promoting immunogenic cell death and attenuating immunosenescence. In conclusion, elevated ferroptosis activity correlates with improved immunotherapy outcomes, potentially through increased tumor immunogenicity and reduced immunosenescence. Ferroptosis-based biomarkers may aid in identifying patients more likely to benefit from immunotherapy.Significance:Ferroptosis, an iron-dependent cell death process, is linked to improved immunotherapy outcomes. In this real-world study across eight cohorts, ferroptosis-high tumors showed 2 to 3 times longer survival. Mechanistically, ferroptosis enhanced immunogenicity and suppressed immunosenescence, highlighting its potential as a biomarker and therapeutic target to boost immunotherapy efficacy.
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Immunotherapy has revolutionized the treatment paradigms of several cancer types, yet only a subset of patients derives durable clinical benefit. Ferroptosis is a programmed cell death facilitated by iron-driven overload of lipid peroxidation. We aimed to evaluate ferroptosis activity based on tumor transcriptomic profiles to determine its predictive value for immunotherapy outcomes. We analyzed RNA sequencing data from eight independent cohorts of patients with urothelial, gastric, skin, and lung cancers treated with immune checkpoint inhibitors or adoptive T-cell therapy. A ferroptosis activity model was constructed using downstream gene expression signatures. Associations with overall survival and progression-free survival were assessed. Potential mechanisms were explored by examining immunosenescence, the IFN-γ immune response pathway, and immunogenic cell death. Ferroptosis-high tumors were associated with significantly improved overall survival and progression-free survival across multiple cancer types. Integrating ferroptosis scores with tumor mutation burden, liver metastasis status, and immune microenvironment phenotypes (inflamed, excluded, desert) enhanced patient stratification and predictive accuracy. Mechanistically, ferroptosis enhanced the immune response by promoting immunogenic cell death and attenuating immunosenescence. In conclusion, elevated ferroptosis activity correlates with improved immunotherapy outcomes, potentially through increased tumor immunogenicity and reduced immunosenescence. Ferroptosis-based biomarkers may aid in identifying patients more likely to benefit from immunotherapy.Significance:Ferroptosis, an iron-dependent cell death process, is linked to improved immunotherapy outcomes. In this real-world study across eight cohorts, ferroptosis-high tumors showed 2 to 3 times longer survival. Mechanistically, ferroptosis enhanced immunogenicity and suppressed immunosenescence, highlighting its potential as a biomarker and therapeutic target to boost immunotherapy efficacy.
- Open Access
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Ferroptosis is associated with favorable treatment outcomes in patients receiving immunotherapy. A, The flow chart shows the design of the study. B, OS analysis of patients based on ferroptosis levels in tumor tissue in the IMvigor210 cohort (urothelial cancers). C, OS analysis of patients based on ferroptosis levels in tumor tissue in the Snyder cohort (melanoma). D, OS analysis of patients based on ferroptosis levels in tumor tissue in the Liu cohort (melanoma). E, OS analysis of patients based on ferroptosis levels in tumor tissue in the Lauss cohort (melanoma). The log-rank test was applied for the survival analysis. GSEA, gene set enrichment analysis.
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Ferroptosis is associated with favorable treatment outcomes in patients receiving immunotherapy. A, The flow chart shows the design of the study. B, OS analysis of patients based on ferroptosis levels in tumor tissue in the IMvigor210 cohort (urothelial cancers). C, OS analysis of patients based on ferroptosis levels in tumor tissue in the Snyder cohort (melanoma). D, OS analysis of patients based on ferroptosis levels in tumor tissue in the Liu cohort (melanoma). E, OS analysis of patients based on ferroptosis levels in tumor tissue in the Lauss cohort (melanoma). The log-rank test was applied for the survival analysis. GSEA, gene set enrichment analysis.
- Open Access
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S5. Prognosis and TMB of non-small cell lung cancer (NSCLC) are associated with ferroptosis level.
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S5. Prognosis and TMB of non-small cell lung cancer (NSCLC) are associated with ferroptosis level.
- Open Access
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S3. Correlation between ferroptosis score and overall survival in cancer patients without receiving immunotherapy.
- 6 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S3. Correlation between ferroptosis score and overall survival in cancer patients without receiving immunotherapy.